1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. EyePoint Pharmaceuticals Acquires Icon Bioscience

M&A Deal Summary

EyePoint Pharmaceuticals Acquires Icon Bioscience

On March 28, 2018, EyePoint Pharmaceuticals acquired life science company Icon Bioscience for 61M USD

Acquisition Highlights
  • This is EyePoint Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is EyePoint Pharmaceuticals’ largest (disclosed) transaction.
  • This is EyePoint Pharmaceuticals’ 1st transaction in the United States.
  • This is EyePoint Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2018-03-28
Target Icon Bioscience
Sector Life Science
Buyer(s) EyePoint Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 61M USD

Target

Icon Bioscience

Newark, California, United States
Icon Bioscience, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome® extended-release drug delivery technology. Icon Bioscience is based in Newark, California.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

EyePoint Pharmaceuticals

Watertown, Massachusetts, United States
Category Company
Founded 1987
Sector Medical Products
Employees121
Revenue 43M USD (2024)
DESCRIPTION

EyePoint Pharmaceuticals is a provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems. EyePoint Pharmaceuticals was incorporated in 1987 and is based in Watertown, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal